Direct Health Care Costs Associated With a Multicomponent COPD Exacerbation Intervention.

Area of Science:

• Health Economics
• Pulmonology
• Public Health

Background:

• Chronic Obstructive Pulmonary Disease (COPD) poses a significant global economic burden, with projected healthcare costs reaching $4.7 trillion over 30 years.
• Rising COPD prevalence necessitates identifying interventions that can reduce healthcare expenditures.
• While self-management interventions for COPD are studied for outcomes and utilization, their impact on healthcare costs remains underexplored.

Purpose of the Study:

• To evaluate the effect of an integrated care program on healthcare costs in patients with COPD and multiple comorbidities.
• To determine if a multicomponent COPD exacerbation prevention management intervention impacts acute and community healthcare costs.

Main Methods:

• A randomized controlled trial involving 462 participants with COPD and multiple comorbidities.
• Data linkage with provincial Canadian health databases to calculate public healthcare costs (acute and community) over 12 months post-randomization.
• Case-costing methods were employed to establish costs for intervention and control groups.

Main Results:

• Total median 12-month in-hospital costs were CAD $4,769 (US $3,566) and community costs were CAD $8,011 (US $5,990).
• The multicomponent COPD intervention resulted in significantly lower community healthcare costs compared to usual care.
• No significant difference in acute care costs was observed between the intervention and control groups after controlling for confounders.

Conclusions:

• The studied COPD intervention effectively reduced community healthcare costs, though acute care costs remained unchanged.
• Community-based healthcare expenditures for COPD patients were substantially higher than acute care costs.
• Future COPD management interventions should consider strategies targeting community care to achieve significant healthcare cost savings.